zura bio is a clinical-stage biotechnology company advancing zb-168 in alopecia areata and other inflammatory diseases. zb-168 is an anti il7rα inhibitor that has the potential to impact diseases driven by il7 and tslp biological pathways. zura bio aims to develop a portfolio of therapeutic indications for zb-168, and is focused on demonstrating its efficacy, safety, dosing convenience and mechanism of action, initially in alopecia areata. this will build on phase 1b data in type 1 diabetes demonstrating a favourable safety profile and strong biological rationale. zura bio is headquartered in london, uk with team members in the uk and usa.
Company profile
Ticker
ZURA, ZURAW
Exchange
Website
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
AMGEN • Gilead Sciences • Biogen • Qiagen • Moderna • BioNTech SE • Sana Biotechnology • Ginkgo Bioworks • Exelixis • Acorda Therapeutics ...
Former names
JATT Acquisition Corp
SEC CIK
ZURA stock data
Latest filings (excl ownership)
EFFECT
Notice of effectiveness
15 Sep 23
424B3
Prospectus supplement
14 Sep 23
8-K
Zura Bio Enters into Sponsored Research Agreement with Benaroya Research Institute
14 Sep 23
S-1/A
IPO registration (amended)
8 Sep 23
S-1/A
IPO registration (amended)
24 Aug 23
8-K
Zura Bio Reports Second Quarter 2023 Financial Results and Recent Business Highlights
14 Aug 23
10-Q
2023 Q2
Quarterly report
14 Aug 23
S-1/A
IPO registration (amended)
11 Aug 23
8-K
Building the Next Immunology Leader Corporate Presentation – July 2023
27 Jul 23
S-1/A
IPO registration (amended)
21 Jul 23
Latest ownership filings
4
Change in insider ownership
22 Jun 23
SC 13D/A
Athanor Capital, LP
22 Jun 23
SC 13G
GREAT POINT PARTNERS LLC
16 Jun 23
SC 13G
SUVRETTA CAPITAL MANAGEMENT, LLC
15 Jun 23
SC 13G
ACCESS INDUSTRIES MANAGEMENT, LLC
15 Jun 23
SC 13G
Deep Track Capital, LP
15 Jun 23
4
Amit Munshi
5 Jun 23
4
Amit Munshi
2 Jun 23
4
Gary Whale
22 May 23
4
Someit Sidhu
22 May 23
Financial summary
| Quarter (USD) | Jun 23 | Mar 23 | Dec 22 | Sep 22 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Annual (USD) | Dec 22 | Dec 21 | |
|---|---|---|---|
| Revenue | |||
| Cost of revenue | |||
| Operating income | |||
| Operating margin | |||
| Net income | |||
| Net profit margin | |||
| Cash on hand | |||
| Change in cash | |||
| Diluted EPS |
| Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
|---|---|---|---|---|---|---|
| Cash on hand (at last report) | 112.80 mm | 112.80 mm | 112.80 mm | 112.80 mm | 112.80 mm | 112.80 mm |
| Cash burn (monthly) | (no burn) | (no burn) | 11.34 mm | 3.75 mm | (no burn) | 420.52 k |
| Cash used (since last report) | n/a | n/a | 31.99 mm | 10.58 mm | n/a | 1.19 mm |
| Cash remaining | n/a | n/a | 80.81 mm | 102.22 mm | n/a | 111.62 mm |
| Runway (months of cash) | n/a | n/a | 7.1 | 27.3 | n/a | 265.4 |
Institutional ownership, Q2 2023
63.3% owned by funds/institutions
| 13F holders | Current |
|---|---|
| Total holders | 42 |
| Opened positions | 38 |
| Closed positions | 16 |
| Increased positions | 0 |
| Reduced positions | 0 |
| 13F shares | Current |
|---|---|
| Total value | 104.84 bn |
| Total shares | 27.62 mm |
| Total puts | 0.00 |
| Total calls | 0.00 |
| Total put/call ratio | – |
| Largest owners | Shares | Value |
|---|---|---|
| Hana Immunotherapeutics | 5.40 mm | $0.00 |
| Ewon Comfortech | 3.65 mm | $0.00 |
| Great Point Partners | 3.30 mm | $27.02 bn |
| PFE Pfizer | 2.97 mm | $0.00 |
| Suvretta Capital Management | 2.85 mm | $23.37 bn |
| JATT Ventures | 2.74 mm | $0.00 |
| Deep Track Capital | 2.52 mm | $20.69 bn |
| Armistice Capital | 950.00 k | $7.79 bn |
| Citadel Advisors | 712.91 k | $5.55 bn |
| Point72 Asset Management | 469.28 k | $3.85 bn |
Recent insider trades
| Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
|---|---|---|---|---|---|---|---|---|---|---|
| 15 Jun 23 | Athanor Capital | Warrants Class A Ordinary Shares | Sell | Dispose S | Yes | No | 0.25 | 1,194,000 | 298.50 k | 0 |
| 5 Jun 23 | Amit Munshi | Class A Ordinary Shares | Buy | Acquire P | No | No | 4.25 | 117,647 | 500.00 k | 617,640 |
| 1 Jun 23 | Amit Munshi | Employee Share Option Class A Ordinary Shares | Grant | Acquire A | No | No | 6.25 | 1,130,000 | 7.06 mm | 1,130,000 |
| 18 May 23 | Kimberly Ann Davis | Class A Ordinary Shares | Grant | Acquire A | No | No | 0 | 492,381 | 0.00 | 492,381 |
| 18 May 23 | Christopher Cabell | Class A Ordinary Shares | Grant | Acquire A | No | No | 0 | 162,060 | 0.00 | 162,060 |
News
Zura Bio Enters into Sponsored Research Agreement with Benaroya Research Institute, Terms Undisclosed
12 Sep 23
Benzinga's Top Ratings Upgrades, Downgrades For August 25, 2023
25 Aug 23
Oppenheimer Initiates Coverage On Zura Bio with Outperform Rating, Announces Price Target of $17
25 Aug 23
Where Zura Bio Stands With Analysts
15 Aug 23
Raymond James Maintains Strong Buy on Zura Bio, Raises Price Target to $22
15 Aug 23